‘Bitten by mosquito: The Big Impact of Going Small’

‘Bitten by mosquito: The Big Impact of Going Small’

Our guest speaker Kamila Koprowska, product manager at SPT Labtech, will talk about how ultra-low volume automation is changing the game in genomics, screening, and chemistry. With practical case studies and lessons from real labs, this talk shows how working at nanolitre-to-microlitre scale can save resources, scale experiments, and unlock previously impractical assays.

register now

Our latest News

discover more
VectorBuilder Wins Two IMAPAC Awards, Cementing Leadership in Gene Therapy and CDMO Innovation

VectorBuilder Wins Two IMAPAC Awards, Cementing Leadership in Gene Therapy and CDMO Innovation

Chicago, IL – SEPTEMBER 30th, 2025 – VectorBuilder, a global leader in the gene delivery space, has won two prestigious awards at the Asia-Pacific Cell and Gene Therapy Excellence Awards 2025 (APCGTEA) and the Asia-Pacific Biologics CDMO Excellence Awards 2025 (APBCEA), hosted by IMAPAC. ● Best Cell & Gene Therapy Supplier Award – AAV Vector Manufacturing ● Best Gene […]

No GPS in the head: How the brain flexibly switches between internal maps

No GPS in the head: How the brain flexibly switches between internal maps

Since their discovery in 2004, the grid cells in the brain, which are important for our orientation, have been regarded as a kind of “GPS in the head.” However, scientists at the German Cancer Research Center (DKFZ) and Heidelberg University Hospital have now shown that grid cells work much more flexibly than previously assumed. In […]

Heidelberg Pharma Advances to Cohort 9 in Phase I/IIa Trial of Lead ATAC Candidate HDP-101 in Multiple Myeloma

Heidelberg Pharma Advances to Cohort 9 in Phase I/IIa Trial of Lead ATAC Candidate HDP-101 in Multiple Myeloma

Ladenburg, Germany, 25 September 2025 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced the initiation of Cohort 9 in its ongoing Phase I/IIa dose escalation trial of HDP-101, the Company’s lead ATAC candidate for the treatment of relapsed or refractory multiple myeloma. The Safety Review Committee […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp